Syros Pharmaceuticals Hematologic Malignancies Pipeline August 2023

Syros Pharmaceuticals presents its clinical development strategy for treating hematologic malignancies, including tamibarotene, SY-2101, and SY-5609. The company outlines multiple near-term catalysts and pivotal trial data expected to advance its portfolio of targeted therapies for myelodysplastic syndrome, acute myeloid leukemia, and acute promyelocytic leukemia. With cash runway extending into 2025, Syros aims to establish new standards of care in frontline hematology treatment.